University of Pennsylvania

University of Pennsylvania

3451 Walnut Street

Philadelphia, PA 19004

United States

Targeting Metabolism as a Therapeutic Approach for High-Risk MYCN-Driven Neuroblastoma

Background

In 30-percent of neuroblastoma cases aberrant activity of the MYCN-gene is present. Current therapies for high-risk MYCN-driven neuroblastoma are ineffective, and only 40% of children with disease can achieve long-term event-free survival. These realities underscore the urgent need to discover novel therapeutic strategies that are more effective in combating neuroblastoma.

Trib2 in the Pathogenesis of T-ALL

Acute Lymphoblastic Leukemia (ALL)

Organ Motion in Children Requiring Radiotherapy to the Abdomen and Chest

Neuroblastoma

Proton Therapy for Treatment of Pediatric Atypical Teratoid Rhabdoid Tumor: Early Outcomes and a Review of the Current Literature

Brain Tumors

Pharmacogenetics of Treatment-Related Cardiac Toxicity in Pediatric AML Patients

Acute Myeloid Leukemia (AML)

Mechanisms Regulating Medulloblastoma Progression

Brain Tumors, Medulloblastoma

Dissecting the Mechanism of Overgrowth and Tumorigenesis in Beckwith-Wiedemann Syndrome

Beckwith-Wiedemann Syndrome, Hepatoblastoma

Background

Beckwith-Wiedemann Syndrome (BWS) is a childhood overgrowth and cancer predisposition disorder due to changes on chromosome 11. Genetic changes similar to those observed in BWS are widespread and have been reported in isolated breast, pancreatic, adrenal, liver, renal, prostate, and colon cancers.

Role of Myosin VI in Pediatric Glioma Proliferation and Invasion

Glioma

Pediatric brain tumors are one of the most common malignancies among children and have been one of the leading causes of cancer-related deaths in the recent times. More than 4000 children in the U.S are diagnosed with some form of pediatric brain tumor everyday ranging from the low grade to the high grade tumors and about 7% of the reported brain tumors occur in children with ages between 0-19 years. High grade tumors like glioblastoma multiforme (GBM) are especially difficult to treat since they grow and spread very rapidly within the brain tissue.

Mothers and Fathers Perspectives: Family Management of Young Adult Survivors of Childhood Brain Tumors

Brain Tumors

While five-year survival rates for survivors of childhood brain tumors have slowly improved to 66% because of advances in care, brain tumor survivors report the lowest quality of life of all childhood cancer survivors. Treatment can affect cognitive and physical functioning in a variety of ways, including neurodevelopmental late effects (changes in overall I.Q., slower processing speed, decline in short-term memory, poor attention span and impaired organizational skills).

The role of overexpressed microRNA’s in the pediatric cancer rhabdomyosarcoma

Rhabdomyosarcoma

Alex's Lemonade Stand Foundation for Childhood Cancer